3SBio Files for IPO

3SBio Inc., a Shanghai, China-based developer of protein-based drugs, has filed for a $123.97 million IPO. It plans to price 7.7 million American depository shares at between $12 and $14 per ADS, and to trade on the Nasdaq under ticker symbol SSRX. UBS is serving as lead underwriter. Shareholders include Walden International.